TRANSVAC
European Network of Vaccine Research and Development
TRANSVAC aims to accelerate the pharmaceutical and clinical development of promising vaccine candidates by bridging the gap between academic research and clinical trails through carefully managing the advancement of promising vaccine candidates from preclinical animal experiments to early proof-of principle studies in humans. Transvac will be the European driving force for vaccine development and will be open and accessible to those interested parties, who are capable of contributing key elements of the strategy, allowing them to leverage the value of the whole consortium. This consortium will comprise the major European stakeholders with an interest in vaccine development, from the scientific community in Europe to the European vaccine manufacturers.
Partner
European Vaccine Initiative (EVI), Germany
Biomedical Primate Research Centre (BPRC), The Netherlands
Helmholtz Centre for Infection Research (HZI), Germany
Vakzine Projekt Management GmbH (VPM), Germany
LIONEX GmbH, Germany
ID-Lelystad (IDL), The Netherlands
UK Health Protection Agency, Centre for Emergency Preparedness and Response (CEPR, formerly CAMR), UK
UK Health Protection Agency, National Institute for Biological Standards and Control (NIBSC), UK
Max Planck Institute for Infection Biology (MPIIB), Germany
University of Regensburg (UREG), Germany
London School of Hygiene & Tropical Medicine (LSHTM), UK
University of Oxford, The Jenner Institute (UOXF), UK
University of Lausanne (UNIL), Switzerland
TuBerculosis Vaccine Initiative (TBVI), The Netherlands
Projektleiter
Beteiligte Gruppen
- Vakzinologie und angewandte Mikrobiologie- Prof. Dr. Carlos A. Guzmán
Sprecher
Carlos Guzman
Koordinator
European Vaccine Initiative (DE)
Homepage
Geldgeber / Förderer
EU - Europäische Union